AbCellera Biologics Inc. Common Shares (ABCL)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 562
- Market Cap
- $3.5B
About AbCellera Biologics Inc. Common Shares
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
SentiSense also tracks daily options readings for AbCellera Biologics Inc. Common Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
AbCellera Biologics Inc. Common Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.